Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSP for Residual Liver Function in Fatty Liver
NCT04546022Phase 2Completed
- Sponsor
- National Defense Medical Center
- Start
- Jul 2007
- Primary completion
- Aug 2007
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of D-galactose in non-alcoholic fatty liver disease (NAFLD), sponsored by National Defense Medical Center. Primary endpoint: Blood concentration of galactose at 60 months. Started Jul 2007; status: completed.
02
Drugs
D-galactose
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04546022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546022.